These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38640165)

  • 41. Strong correlation between the 6-minute walk test and accelerometry functional outcomes in boys with Duchenne muscular dystrophy.
    Davidson ZE; Ryan MM; Kornberg AJ; Walker KZ; Truby H
    J Child Neurol; 2015 Mar; 30(3):357-63. PubMed ID: 24762862
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Safety and efficacy of givinostat in boys with Duchenne muscular dystrophy (EPIDYS): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Mercuri E; Vilchez JJ; Boespflug-Tanguy O; Zaidman CM; Mah JK; Goemans N; Müller-Felber W; Niks EH; Schara-Schmidt U; Bertini E; Comi GP; Mathews KD; Servais L; Vandenborne K; Johannsen J; Messina S; Spinty S; McAdam L; Selby K; Byrne B; Laverty CG; Carroll K; Zardi G; Cazzaniga S; Coceani N; Bettica P; McDonald CM;
    Lancet Neurol; 2024 Apr; 23(4):393-403. PubMed ID: 38508835
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial.
    Hafner P; Bonati U; Rubino D; Gocheva V; Zumbrunn T; Gueven N; Fischer D
    Trials; 2016 Aug; 17(1):389. PubMed ID: 27488051
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Neck flexor muscle strength and its relation with functional performance in Duchenne muscular dystrophy.
    Bozgeyik S; Alemdaroğlu İ; Bulut N; Yılmaz Ö; Karaduman A
    Eur J Paediatr Neurol; 2017 May; 21(3):494-499. PubMed ID: 28034620
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Ankle contractures and functional motor decline in Duchenne muscular dystrophy.
    Woof AL; Selby K; Harris SR
    Brain Dev; 2022 Feb; 44(2):105-113. PubMed ID: 34629214
    [TBL] [Abstract][Full Text] [Related]  

  • 46.
    Muntoni F; Signorovitch J; Sajeev G; Lane H; Jenkins M; Dieye I; Ward SJ; McDonald C; Goemans N; Niks EH; Wong B; Servais L; Straub V; Guglieri M; de Groot IJM; Chesshyre M; Tian C; Manzur AY; Mercuri E; Aartsma-Rus A;
    Neurology; 2023 Apr; 100(15):e1540-e1554. PubMed ID: 36725339
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Moving towards meaningful measurement: Rasch analysis of the North Star Ambulatory Assessment in Duchenne muscular dystrophy.
    Mayhew A; Cano S; Scott E; Eagle M; Bushby K; Muntoni F;
    Dev Med Child Neurol; 2011 Jun; 53(6):535-42. PubMed ID: 21410696
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials.
    McDonald CM; Sajeev G; Yao Z; McDonnell E; Elfring G; Souza M; Peltz SW; Darras BT; Shieh PB; Cox DA; Landry J; Signorovitch J;
    Muscle Nerve; 2020 Jan; 61(1):26-35. PubMed ID: 31599456
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Recombinant human insulin-like growth factor-1 therapy for 6 months improves growth but not motor function in boys with Duchenne muscular dystrophy.
    Rutter MM; Wong BL; Collins JJ; Sawnani H; Taylor MD; Horn PS; Backeljauw PF
    Muscle Nerve; 2020 May; 61(5):623-631. PubMed ID: 32108355
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Six-minute walk test versus two-minute walk test in children with Duchenne muscular dystrophy: Is more time more information?
    Vill K; Ille L; Schroeder SA; Blaschek A; Müller-Felber W
    Eur J Paediatr Neurol; 2015 Nov; 19(6):640-6. PubMed ID: 26455815
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy.
    Muntoni F; Domingos J; Manzur AY; Mayhew A; Guglieri M; ; Sajeev G; Signorovitch J; Ward SJ
    PLoS One; 2019; 14(9):e0221097. PubMed ID: 31479456
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of ambulatory capacity and disease progression of Duchenne muscular dystrophy subjects enrolled in the drisapersen DMD114673 study with a matched natural history cohort of subjects on daily corticosteroids.
    Goemans N; Tulinius M; Kroksmark AK; Wilson R; van den Hauwe M; Campion G
    Neuromuscul Disord; 2017 Mar; 27(3):203-213. PubMed ID: 28169120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Selection Approach to Identify the Optimal Biomarker Using Quantitative Muscle MRI and Functional Assessments in Becker Muscular Dystrophy.
    van de Velde NM; Hooijmans MT; Sardjoe Mishre ASD; Keene KR; Koeks Z; Veeger TTJ; Alleman I; van Zwet EW; Beenakker JM; Verschuuren JJGM; Kan HE; Niks EH
    Neurology; 2021 Aug; 97(5):e513-e522. PubMed ID: 34162720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disease progression rates in ambulatory Duchenne muscular dystrophy by steroid type, patient age and functional status.
    McDonald CM; Marden JR; Shieh PB; Wong BL; Lane H; Zhang A; Nguyen H; Frean M; Trifillis P; Koladicz K; Signorovitch J
    J Comp Eff Res; 2023 Apr; 12(4):e220190. PubMed ID: 36749302
    [No Abstract]   [Full Text] [Related]  

  • 55. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Reliability and validity analyses of the North Star Ambulatory Assessment in Brazilian Portuguese.
    Okama LO; Zampieri LM; Ramos CL; Toledo FO; Alves CRJ; Mattiello-Sverzut AC; Mayhew A; Sobreira CFR
    Neuromuscul Disord; 2017 Aug; 27(8):723-729. PubMed ID: 28648683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Functional outcome measures in young, steroid-naïve boys with Duchenne muscular dystrophy.
    Mayhew AG; Moat D; McDermott MP; Eagle M; Griggs RC; King WM; James MK; Muni-Lofra R; Shillington A; Gregson S; Pallant L; Skura C; Staudt LA; Eichinger K; McMurchie H; Rabb R; Di Marco M; Brown S; Zanin R; Arnoldi MT; McIntyre M; Wilson A; Alfano LN; Lowes LP; Blomgren C; Milev E; Iodice M; Pasternak A; Chiu A; Lehnert I; Claus N; Dieruf KA; Rolle E; Nicorici A; Andres B; Hobbiebrunken E; Roetmann G; Kern V; Civitello M; Vogt S; Hayes MJ; Scholtes C; Lacroix C; Gunn T; Warner S; Newman J; Barp A; Kundrat K; Kovelman S; Powers PJ; Guglieri M;
    Neuromuscul Disord; 2022 Jun; 32(6):460-467. PubMed ID: 35618576
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Characteristics of disease progression and genetic correlation in ambulatory Iranian boys with Duchenne muscular dystrophy.
    Zamani G; Hosseinpour S; Ashrafi MR; Mohammadi M; Badv RS; Tavasoli AR; Akbari MG; Bereshneh AH; Malamiri RA; Heidari M
    BMC Neurol; 2022 May; 22(1):162. PubMed ID: 35501714
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations.
    McDonald CM; Henricson EK; Han JJ; Abresch RT; Nicorici A; Atkinson L; Elfring GL; Reha A; Miller LL
    Muscle Nerve; 2010 Dec; 42(6):966-74. PubMed ID: 21038378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.